Receptos to Present at the 2012 Wedbush PacGrow Life Sciences Management Access Conference
Published: Aug 13, 2012
SAN DIEGO, Aug. 13, 2012 /PRNewswire/ -- Receptos Inc. today announced that the company is scheduled to present at the 2012 Wedbush PacGrow Life Sciences Management Access Conference at 9:10 a.m. EDT on Wednesday, August 15, 2012, at the Le Parker Meridien Hotel in New York City. Faheem Hasnain, president and chief executive officer, will provide an overview of the company and an update about its Phase 2 clinical development programs for multiple sclerosis and inflammatory bowel disease with RPC1063.
About RPC1063 and S1P1 Agonists
RPC1063 is a novel, differentiated sphingosine 1-phosphate 1 receptor (S1P1) selective agonist exhibiting picomolar potency that is effective in rodent models of both multiple sclerosis (MS) and inflammatory bowel disease (IBD), and possesses an excellent safety profile in non-clinical toxicology studies. Receptos has completed a Phase 1 clinical safety study with RPC1063 under a US IND that supports the desired differentiation profile and establishes justification for initiation of MS and IBD clinical efficacy trials in 2012. S1P1 is a G protein-coupled receptor (GPCR) that binds the lipid signaling molecule sphingosine 1-phosphate (S1P). S1P is a circulating lipid that binds to five GPCRs termed S1P1-5. S1P1 selectively regulates physiological functions in the immune and cardiovascular systems, including immune cell trafficking and the maintenance of endothelial integrity. In autoimmune disorders, S1P1 agonism works by selectively sequestering circulating lymphocytes, blunting the underlying cause of disease.
Receptos is a biopharmaceutical company developing autoimmune therapeutic candidates through information - driven drug discovery, including GPCR structure determination. The company's lead program, RPC1063, is a best-in-class S1P1 small molecule agonist candidate for autoimmune indications. Receptos' expertise in S1P1 biology has been informed by the company's high resolution protein crystal structure of the S1P1 receptor, published in Science earlier this year. Receptos has established partnerships for its GPCR structure determination technology platform with Eli Lilly, Ono Pharmaceutical and Janssen Pharmaceuticals, Inc. For more information visit www.receptos.com.
SOURCE Receptos Inc.